Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionano Genomics

Tesla

Select analysts and pundits foresee game-changing upside from this fast-paced trio.

3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street

AMC Entertainment

Himax Tech

Hyzon Motors

Peloton

Redfin

Vroom

Financial markets have been in turmoil for the better part of the past six months. The stock market has plunged to new lows as the Federal Reserve tightens the screws with rampant interest rate hikes.

Warning! Don't Even Consider Buying These 7 Dead-Money Stocks

MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Tuesday, November 8, 2022.

Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

Highlighting Ocugen research and innovative technologies

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

•  No safety concerns noted in ongoing clinical trial •  Study timeline remains on track

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.

Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6 th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY.

Ocugen, Inc. to Present at Chardan's 6th Annual Genetic Medicines Conference

MALVERN, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the company has entered into an exclusive license agreement with Washington University in St. Louis, MO for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered COVID-19 vaccine in the United States, Europe, and Japan. This vaccine is already authorized for emergency use in India and is an important addition to Ocugen's COVID-19 vaccine portfolio.

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

MALVERN, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 148,800 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 40,092 shares of common stock to five newly hired team members. The stock options and RSUs were granted as of September 16, 2022, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” appeared in Frontiers in Immunology. BBV152, commercialized as COVAXIN™, is developed and manufactured by Ocugen's partner Bharat Biotech, a global leader in vaccine innovation based in Hyderabad, India. BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, and accepted as a COVID-19 vaccine to travel into over 85 countries. It is under clinical investigation by Ocugen in the United States for use in adults aged 18 years and older.

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

Bed Bath & Beyond

Coinbase

Disney

MicroStrategy Incorporated

Mullen Automotive

As Washington's fiscal and monetary stimulus has wound down, meme stocks and cryptocurrencies are tumbling tremendously. Consequently, any names connected to either phenomenon are good growth stocks to sell.

7 Growth Stocks to Sell Now

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company's Chief Scientific Officer, Arun Upadhyay, PhD, will be among the featured speakers at the 3 rd Annual Gene Therapy for Ophthalmic Disorders conference, which is being held Sept. 13-16 in Danvers, Massachusetts.

Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright 24 th Annual Global Investment Conference being held September 12-14, 2022 in New York, NY.

Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference

The company appointed not one, but two new top managers to crucial posts.

Why Ocugen Stock Topped the Market Today

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer. Arun Upadhyay, PhD, previously Senior Vice President, Research & Development, will now serve as the Company's Chief Scientific Officer, overseeing the development and manufacturing of Ocugen's clinical and commercial product portfolio and evaluating new technologies.

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

An analyst thinks the biotech could have an important new gene therapy on its hands.

Why Ocugen Stock Is Racing Higher Today

Amarin Corporation Plc

This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.

Are Ocugen or Amarin Good Penny Stocks to Buy?

Source: Wirestock Creators / Shutterstock.com Ocugen (NASDAQ: OCGN ) stock is gaining on Tuesday after Mizuho Securities analysts initiated coverage of the medical company's shares. That coverage starts with a “buy” rating for OCGN stock.

Why Is Ocugen (OCGN) Stock Climbing Higher Today?

A moonshot won't be necessary, but it'll require a bit of a pivot.

Here's How This Beaten-Down Stock Could 10X by 2024

MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2 nd Annual Ophthalmology Virtual Conference on August 17.

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Ocugen, Inc. (NASDAQ:OCGN ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer and Co-Founder Jessica Crespo - Chief Accounting Officer and Senior Vice President, Finance Conference Call Participants Jennifer Kim - Cantor Jonathan Aschoff - ROTH Capital Partners Daniil Gataulin - Chardan Robert LeBoyer - Noble Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Good morning and welcome to the Ocugen Second Quarter 2022 Business Update and Financial Results Call.

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q2 2022 Results - Earnings Call Transcript

Conference Call and Webcast Today at 8:30 a.m. ET Conference Call and Webcast Today at 8:30 a.m. ET

Ocugen Provides Business Update & Second Quarter 2022 Financial Results

Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.

Ocugen Q2 Preview: Rebound Quarter Inbound?

MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and gene therapies and vaccines, today announced that it will host a conference call and simultaneuous webcast to discuss the Company's second quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Friday, August 5, 2022.

Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

Sorrento Therapeutics Inc

VBI Vaccines

Healthcare has become a bona fide stock picker's market this year.

News for Ocugen, Inc. Stock (OCGN)